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Fibroblasts derived from the involved skin of scleroderma 
patients frequently display a phenotype of supernormal col-
lagen expression when cultured. Fibroblasts displaying this 
phenotype derived from seven patients were treated with 
r~laxin (1-100 ngjml) and interferon-y (1-100 U jml), indi-
vidually and in combination, to assess the relative abilities of 
these cytokines to down-modulate collagen synthesis and 
S~cretion. Scleroderma fibroblasts displayed varying sensitivi-
ties to both relaxin and interferon-yo Relaxin (100 ng/ml) 
decreased expression of collagen by six of seven lines tested 
from 8 to 59% compared to untreated cultures. Interferon-y 
(100 U jml) depressed collagen secretion by all seven lines in 
C onnective tissue turnover is normally an orderly pro-cess in which the breakdown of extracellular matrix molecules is offset by the synthesis of new elements. This balance, which is critical to normal growth and development, is temporarily altered in response to 
traumatic or pathologic tissue injury to effect tissue repair. How-
ever, in certain pathologies, such as scleroderma (progressive sys-
temic sclerosis) , this balance is chronically skewed in the direction 
of matrix over-production, resulting in excessive fibrosis of the skin, 
gastrointestinal tract, and other organ systems [1]. Fibroblasts cul-
tured from scleroderma lesions synthesize increased amounts of col-
lagen [2,3]' glycosaminoglycans [4], and fibronectin [4,5]. This un-
regulated expression of extracellular matrix molecules is thought to 
be. responsible for much of the tissue and organ damage manifest in 
thiS disease. 
We have previously shown that synthetic human relaxin can 
doWn-regulate the collagen secretory phenotype of normal human 
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a range from 7 to 89%. When relaxin and interferon-y were 
used in combination, relaxin augmented IFN-y- induced de-
creases in collagen secretion in four of seven lines. In three of 
these lines, the use of relaxin in conjunction with suboptimal 
doses of interferon-y resulted in decreases equivalent to or 
greater than that seen with a tenfold higher concentration of 
interferon-yo This study demonstrates the ability of relaxin to 
directly alter the excessive collagen-producing phenotype of 
scleroderma fibroblasts. In addition, in some cases, combin-
ing relaxin and interferon-y resulted in a cooperative effect in 
decreasing collagen expression by scleroderma cells in vitro.] 
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dermal fibroblasts, especially when the cells are stimulated to over-
produce collagen, such as by treatment with the cytokines trans-
forming growth factor-p (TGF-P) or interleukin-1p (IL-IP) [6]. 
This occurs in conjunction with a dose-dependent increase in the 
secretion of the metalloproteinase procollagenase and a small de-
crease in tissue inhibitor of metalloproteinases, suggesting that re-
laxin may be able to modulate connective tissue turnover in favor of 
net collagen breakdown in situations of collagen overexpression. 
Previously published work has shown that interferon-y (IFN-y) is a 
potent down-regulator of collagen expression in scleroderma [7], 
normal [8-10]' and rheumatoid synovial [10] fibroblasts. These 
findings were the bases of the current work, in which scleroderma 
fibroblasts were treated with relaxin alone and in conjunction with 
IFN-y to see i) whether relaxin could down-regulate collagen secre-
tion in these fibroblasts and ii) whether the combination of relaxin 
and IFN-y could be as or more effective than either agent individu-
ally in effecting a significant decrease in collagen secretion. 
METHODS 
Cell Culture Scleroderma fibroblast cell lines were derived from 
full-thickness skin biopsy specimens from patients who fulfilled the 
American Rheumatism Association criteria for the diagnosis of scle-
roderma [11]. Paired skin biopsies from the uninvolved skin of 
patients were also available in some cases. Explant cultures were 
maintained in Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and 2 mM L-gluta-
mine until a confluent monolayer of fibroblasts had been estab-
lished. Cultures were then expanded using a 1: 3 split in 
DMEM-FBS until an adequate number of cells was obtained for 
experiments. Normal dermal fibroblasts obtained from explant cul-
ture of normal human skin obtained from rhytidectomy or from the 
American Type Culture Collection (ATCC CRL1471) were used 
between passages 1 and 7. Cells were counted at each passage using a 
hemocytometer to assess saturation densitites of the different lines. 
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Figure 1. (A) Identification of procollagen bands by sensitivity to bacterial 
collagenase and (B) quantitation of procollagens expressed by normal and 
scleroderma cultures. (A) 3H-proline-labeled proteins secreted by fibroblast 
cultures were subjected to digestion with purified bacterial collagenase at 
37 0 C for 6 h. precipitated. and electrophoresed on a 7% polyacrylamide gel. 
Procollagens. which migrate as several partially processed bands in the ab-
sence of bacterial collagenase (bact eL) digestion (-). are degraded in the 
presence of collagenase (+). (B) Autoradiograms. which included procolla-
gen precipitated from both normal and scleroderma cultures. were scanned 
desnitometrically. Densities were plotted such that the average amount of 
procollagen expressed by normal cultures of dermal fibroblasts was equiva-
lent to 1.0. Densitometric values were normalized for differences in satura-
tion density of the cultures. Seven lines secreted 1.5 - 4.3 times more procol-
lagen than normal cells on a per cell basis. 
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Figure 2. Relaxin dose-dependent decreases in procollagen expression by 
three scleroderma lines. Cultures treated with relaxin (1-100 ng/ml) were 
labeled with 3H-proline as described in the Materials mId Metllods sectiOn. 
Labeled proteins resolved by electrophoresis were analyzed densitometn-
cally on autoradiograms. Lines were found to respond consistently to treat-
ments among experiments. Bar. average of two replicate cultures within one 
experiment. Standard error was less than 10% in each case. 
2 . 
For experiments. all cells were seeded at 6.25 X 104 cells/cm 10 
DMEM + FBS in 24- or 48-well plates. At 72 h. the cells were 
washed and the medium replaced with DMEM supplemented with 
0.2% lactalbumin hydrolysate and 2 roM L-giutamine. Cells were 
treated with cytokines in this serum-free medium for 48 h. 
Reagents Bioactive human relaxin was either chemically synthe-
sized as predicted from the sequence of the human relaxin gene I-I2 
[12] or expressed as a recombinant protein in a mammalian expres-
sion system [13] . No differences in bioactivity have been noted 10 
the relaxin from the two sources. IFN-y was recombinant. human 
(Genentech. specific activity 2.65 X 107 U/mg) [14] . Asco~bate 
and /l-aminopropionitrile (BAPN) were purchased from Sigma 
and prepared as 50 and 80 mg/ml stocks. respectively. in DME~ 
immediately prior to use. L[2.3-3H]proline (specific activity 30 Ct~ 
mmol). [35S]methionine (specific activity 1213 Ci/mmol) . an 
[32P]dCTP (specific activity 2000 Ci/mmol) were purchased from 
Amersham . 
Biosynthetic Labeling and SDS-PAGE For analysis of colla-
gen synthesis and secretion. cells were labeled with 3H-proline (2~ 
,uCi/ml) in DMEM in the presence of 50 ,ug/ml ascorbate and 8 
,ug/ml BAPN for 18 h at 37°C. In experiments where cultures were 
treated with IFN-y and relaxin. cytokines were present during the 
labeling period. Biosynthetically labeled secreted proteins were pre-
cipitated from the conditioned media using 0.02 M quinine sulfatd 
and 0.2% SDS [15]. resuspended in Laemmli sample buffer [1 .6]. an I 
electrophoresed on 7% polyacrylamide gels using a 3% stacking gi. 
under reducing conditions according to the method of Laemrn I 
[16] . In some experiments. radiolabeled proteins were tested for 
sensitivity to bacterial collagenase (100 units/ml) (Advance BiOfac-
tures) for 6 h at 37°C to identify collagenous proteins [15]. colla-
gens were also characterized according to migration on a 5% polyacd 
rylamide gel following limited pepsin digestion [17] and delayed 
reduction [18] . Gels were enhanced (New England Nuclear). dne . 
and exposed to X-Omat film (Kodak) at - 80°C. Collagen bands 0;. 
the radiograms were scanned densitometrically on a Microtek 0S 
300GS .image scanner and the areas under the entire bands 1I1te-
grated using the National Institutes of Health Image 1.23 h pro-
gram on a MacIntosh II computer (Apple Computers) . I 
To assess the relative effects of relaxin and IFN-y on the to.t~ 
amount of protein secreted. cultures were also labeled for 18 ~ WI~ 1 
[35S]-methionine (25 ).lCi/ml) in methionine-free DMEM 111 t/ 
presence of cytokines . Protein was precipitated from the cond 1_ 
tioned media with quinine-sulfate-sodium dodecyl sulfate. as e 
scribed above. and aliquots counted in a scintillation counter. 
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Table I. 
Scleroderma 
Line 
S05 
SOlO 
SOl1 
S014 
S016 
S017 
S018 
Responsiveness of Scleroderma Lines to Maximum 
Individual Doses of Relaxin and IFN-y 
Effect on Collagen Synthesis' 
Relaxin' (%.1.) IFN-y' (%.1.) 
-14% -38% 
-10% -30% 
-31% -46% 
- 8% - 7% 
-59% -89% 
-76% -85% 
0% -84% 
• Collagen bands on auto radiograms were scanned densitometrically to quantitate 
effects of relaxin and IFN-y on collagen protein expression by seven scleroderma (SD) 
hnes . All lines were subjected to nine treatment regimens in duplicate in at least two 
eXperiments. Decreases in collagen expression induced by treatments were consistent 
among experiments for each line. %t. was obtained by calculating the average change in 
Collagen expression by cultures treated in duplicate with that of the untreated control 
culture in one representative experiment. Standard error was less than 10% in each case. 
b Relaxin effect was assessed at 100 ng/m!. 
' IFN_y effect was observed at 100 U/m!. 
RESULTS 
All scleroderma lines included in this study demonstrated enhanced 
collagen expression when compared to normal dermal fibroblasts or 
fibroblasts from the uninvolved skin of the same patient, when 
available, as ascertained by densitometric analysis of labeled colla-
gen bands on autoradiograms, as described below. Normal and scle-
roderma fibroblasts were labeled in DMEM in the absence of serum 
for 18 h with 3H-proline in the presence of ascorbate, a co-factor 
required for collagen synthesis, and BAPN, an agent that inhibits 
c.ollagen cross-linking, as described in the Materia ls and Methods sec-
tion. Biosynthetically labeled secreted proteins from normal and 
s~ l eroderma cultures were precipitated from equal volume~ of con-
ditioned media and electrophoresed on 7% polyacrylamide gels. 
Procollagen was identified as the two most prominent proline-in-
corporating bands on the radiogram by sensitivity to digestion by 
purified bacterial collagenase (Fig 1A). To provide a normal refer-
ence for relative quantity of collagen synthesized by scleroderma 
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fibroblast cultures, procollagen precipitated from a normal fibro-
blast culture was electrophoresed alongside those from scleroderma 
cultures. Procollagen bands were scanned densitometrically, as de-
scribed in the Materials and Methods section; these areas were plotted 
as relative numbers such that the amount of collagen secreted by a 
normal dermal fibroblast culture was equal to 1.0. Differences in the 
saturation densities of the cell lines at confluence were noted (data 
not shown); therefore, values for relative amount of collagensynthe-
sized were normalized for cell number per culture dish. Scleroderma 
lines were compared with normal cultures over two-four experi-
ments and lines whose comparative collagen expression values were 
higher than normal by at least 50% were selected for this study. 
Seven scleroderma lines secreted 1.5 - 4.3 times more collagen than 
normal fibroblasts (Fig IB) and were analyzed for responsiveness to 
cytokine treatment. 
To assess the sensitivity of cultures of scleroderma cultures to 
relaxin, cells were cultured as described above and treated 72 h later 
in duplicate wells with relaxin (1,10, and 100 ng/ml) for 48 h. At 
the end of this period, cells were labeled with 3H-proline in the 
presence of cytokines, ascorbate, and BAPN for 18 h. All seven lines 
were tested in two separate experiments and response patterns were 
consistent between experiments for each line. Three lines, SDll , 
SD 16, and SD 17, were sensitive to relaxin treatment and mani-
fested dose-dependent decreases in collagen expressiolJ., with maxi-
mum decreases of 29%, 59%, and 76%, respectively, at a relaxin 
dose of 100 ng/ml (Fig 2) . Three other scleroderma lines demon-
strated smaller decreases in collagen expression ranging from 8% to 
14% in response to relaxin (100 ng/ml) (Table I) . One line, SD18, 
showed no consistent response to relaxin. Total secreted protein, as 
assessed by [35S)methionine incorporation into quinine sulfate-
SDS - precipitable material, increased 25% over control levels with 
the maximum dose of relaxin. 
The seven scleroderma lines were tested individually for IFN-y 
sensitivity (100 U /ml) and responded with decreases in collagen 
synthesis and secretion from ranging from 7 to 89% (Table I) . These 
results are consistent with previously published reports on the ef-
fects ofIFN-y on collagen expression by scleroderma fibroblasts [9) . 
The ability of relaxin and IFN-y to alter patterns of collagen 
expression when used in combination was then tested on the sclero-
derma fibroblasts. Scleroderma cultures were treated with relaxin 
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Figure 3. Effects of combinational treatment of relaxin and IFN-y on scleroderma line SO 5. (AJ Cells treated with relaxin (Rlx) or IFN-y individually 
demonstrated some decrease in procollagen expression, but the combination ofIFN-y at 10 V /ml and R1x (1-100 ng/ ml) achieved a greater down-regulation 
than ei ther cytokine individually, including that seen with IFN-y at 100 U /m!. The relative amount of procollagen expressed by a culture of fibroblasts derived 
from the uninvolved skin of the same patient (Norm) is shown for comparison. (B) Densitometric analysis of the autoradiogram shown in A demonstrates 
Significant down-modulation by the combination of relaxin and IFN-y and a relaxin dose-dependent decrease in procollagen expression when used in 
Conjunction with IFN-y at 10 U / m!. (C) Separation of the collagen chains following limited pepsin digestion and delayed reduction during electrophoresis 
t emonstrates that the a t(I), a2(1), and a t(III) chains are equally decreased from untreated levels (-) following treatment (+) with relaxin (100 ng/ml) and 
FN_y (100 V/ ml). 
340 UNEMORI ET AL 
(1,10, and 100 ng/ml) in combination with IFN-y (1,10, and 100 
U /ml) such that all three relaxin doses were tested in conjunction 
with all three doses of IFN-y, resulting in nine combination treat-
ment groups. Four of seven lines tested demonstrated a cooperative 
effect of using both cytokines together in depressing collagen ex-
pression. Scleroderma line, SD5, which demonstrated responses of 
moderate magnitude to relaxin and IFN-y individually (Table I), 
showed striking decreases in secreted collagen in the presence of 
both cytokines (Fig 3A,B, Table II) . A suboptimal dose ofIFN-y (10 
U /ml) in conjunction with low concentrations of relaxin (1 and 10 
ng/ml) effected decreases of 58% and 62% in collagen expression, 
depressions not approached when maximum doses of either relaxin 
(100 ng/ml) or IFN-y (100 U/ml) were used individually. The 
augmenting effect of relaxin on collagen 'depression occurred in a 
dose-dependent manner. Limited pepsin digestion and delayed re-
duction analysis of the collagen chains demonstrated roughly equiv-
alent decreases in expression of the a l (I), ail), and a l (III) chains by 
treatment with the combination of cytokines (Fig 3C). The coordi-
nate decreases in expression of all three chains that comprise types I 
and III procollagens were similar to changes induced by IFN -Y alone 
[10]. 
In the cases ofSDll and SD18, the addition of relaxin in conjunc-
tion with suboptimal concentrations ofIFN-y resulted in decreases 
in collagen secretion equivalent to that seen following treatment 
with a tenfold higher dose of IFN-y (Fig 4). Treatment of SDll 
fibroblasts with relaxin (100 ng/ml) or IFN-y (10 U /ml) individu-
ally caused a 29% or 41 % decrease in collagen expression, respec-
tively (Fig 4A). The addition of the two agents together resulted in a 
53% decrease, equivalent to that seen when IFN-y was used at a 
tenfold higher concentration, 100 U/ml (Table II). SD18 showed 
no consistent. response to treatment with relaxin alone but when 
relaxin was used in combination with IFN-y, decreases in collagen 
expression exceeded that seen by using IFN-y alone (Fig 4B). An-
other scleroderma line, SD14, which was relatively resistant to re-
laxin and IFN-y when the cytokines were tested individually, dem-
onstrated an additive response when they were used in combination. 
Whereas IFN-y and relaxin individually effected 7% and 8% de-
pressions in collagen expression, respectively, their combination 
resulted in a 17% decrease in collagen secreted (Table II). No addi-
tive or synergistic effects of the two cytokines were observed follow-
ing treatment of scleroderma lines SD 10, 16, or 17. None of the 
combination treatments caused a change in total secreted protein 
(data not shown). 
DISCUSSION 
The coordinated assembly and disassembly of collagen and other 
matrix elements allows for tissue growth and repair and provides 
developmental and differentiation cues that are critical to proper 
form and function of multicellular animals. When this precise regu-
lation of connective tissue turnover is disrupted, severe problems in 
form and function do occur. Fibroblasts derived from the sclerotic 
skin of scleroderma patients can demonstrate markedly elevated 
levels of collagen synthesis and secretion as compared to normal 
dermal fibroblasts [2,3]. The overproduction of collagen and other 
extracellular matrix constituents [4,5] are thought to cause the pro-
gressive fibrosis that leads to tissue damage in this disease. 
Previously reported work has shown that IFN-y can be effective in 
decreasing collagen synthesis in scleroderma fibroblasts [7]. These 
and subsequent studies that have shown that IFN-y can decrease 
collagen accumulation in vivo [19 - 21] were the bases for the initia-
tion of limited clinical trials to test the efficacy of IFN-y in the 
treatment of scleroderma and ke10ids [22-24]. The hormone re-
laxin has been shown to be effective in decreasing collagen expres-
sion in normal dermal fibroblasts in vitro, particularly when signifi-
cant collagen overexpression is induced by the cytokines TGF-fi or 
IL-lfi [6]. Recently, we have also shown that relaxin is capable of 
inhibiting fibrosis in two animal models [25]. In the present study, 
we have extended these findings by demonstrating that relaxin can 
down-regulate collagen expression in scleroderma fibroblasts and 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
B 
A 
1.5 -y-----------, 
.~ 
c 
:::> 1.0 
~ 
Q) 
E 
.8 
'w 0.5 
c 
<D 
o 
0.0 
Rlx (ng/ml): 0 
IFN-y (U/ml): 0 
100 0 
o 10 
S011 
100 0 
10 100 
2 ~------------------~ 
(/) 
.~ 
C 
~ 
>. 
~ 
...... Q) 
E 
o 
...... 
. U) 
C 
Q) 
o 
o 
Rlx (1 OOng/ml): 
IFN-y(1 U/ml): 
+ 
+ 
+ 
+ 
Figure 4. Effects of combinational treatment of relaxin (Rlx) and lFN-yon 
line scleroderma lines (A) 5011 and (B) 5018. (A) Densitometric analysl: 
of the autoradiograms demonstrates that treatment of scleroderma line SD\ 
with relaxin and IFN-y in combination results in as much decrease in proCo Ii 
lagen expression as ('ffected by 100 U/ml IFN-y. (B) Treatment ofSpl 
fibroblasts with relaxin alone had no effect but the addition of relax1l1/ t1 
lFN-y (1 V/ml) resulted in a decrease greater than that seen with 10 U md 
IFN-y. Bar, average of two replicate wells within one experiment. Standar 
error was less than 10% in each case. 
have also shown that the two collagen inhibitory cytokines, rela~in 
and IFN-y, have greater potential utility when used in combinatiOn 
than when used individually. 
Consistent with our previous findings that relaxin is a potent 
collagen down-regulatory cytokine under conditions when c~lls a~e 
overproducing collagen, relaxin can depress collagen expresslOll
11
!-
scleroderma fibroblasts that are stimulated to produce excess co 
gen. The basis for the differences in sensitivity of the scleroderrnd lines to relaxin treatment is unknown. We and others have observ~ 
a similar variability of sensitivity of lines to IFN-y treatment .. ~ ~ 
differences may lie in receptor number or affinity, although dl er. 
ences in intracellular signaling pathways may also be relevant. Be 
cause the etiology and biochemical basis of the disease scleroderrnj 
are unknown, in what aspects these cells have deviated from n?r~a. 
are difficult to assess. The fact that the clinical designatIOn of sc e 
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Table II. Summary of Relaxin and IFN-y Cooperativity in 
Inhibiting Collagen Synthesis by Scleroderma Fibroblasts 
Scleroderma 
Line 
S05 
SOlI 
S014 
S018 
Effect on Collagen Synthesis' 
Relaxinb (%Ll) IFN-y' (%Ll) Combinationd (%Ll) 
-14% -38% -69% 
-29% -41% -53% 
- 8% - 7% -17% 
0% -37% -88% 
• Decreases in collagen expression were calculated as described in Table I. 
b Relaxin effect obtained at a dose of 100 ng/ml in all cases. 
, IFN-yeffect observed at 10 Vlml for 5011,1 Vim I forSOl8, and at 100 Vlml for 
SDS and S014. 
'Effect of combining relaxin and IFN-y at doses used in individual treatments, 
descnbed in footnotes band c. 
roderma" may actually represent a cluster of diseases manifesting a 
similar collagen-overexpressing phenotype is a further complicat-
Ing factor. However, the question of differences in relaxin binding 
to scleroderma lines displaying high and low sensitivity to relaxin is 
now being addressed by doing binding studies using radiolabeled 
relaxin. 
The mechanism by which relaxin depresses collagen expression is 
undetermined but its abi lity to do so under a variety of conditions 
Suggests an important target. For example, r~laxin can inhib~t colla-
gen synthesis by normal dermal fibroblasts m culture, parucularly 
when stimulated by TGF-p or IL-1P in the presence of mdometha-
Cin [6]. It is also a potent collagen inhibitory agent in vivo, as demon-
strated when tested in two rodent models of fibrosIs [25]m which a 
number of cytokines are likely to be participating in stimulating 
coliagen synthesis. Therefore, the fact that it can also decrease colla-
~en secretion by scleroderma fibroblasts suggests that it is impi~g­
Ing at a common point in the collagen stimulatory pathways tng-
gered by a number of agonists. IFN-y has been reported to decrease 
Collagen expression primarily by causing mRNA instability [28]. Its 
additive or synergistic cooperativity with IFN-y in decreasmg colla-
gen expression suggests complex interactions between the two cy-
tokines; interactions at the intracellular signaling pathway level or 
at the level of receptor number or affinity cannot be excluded. 
The systemic administration of IFN-y to humans at pharmaco-
logic doses is accompanied by some adverse reactions, predomi-
nantly flu-like symptoms [23,24,27]. Consequently, it is desirable 
to. keep the administered dose as low as possible while still main-
taining the desired effect. In the [resent study, we evaluated the 
effectiveness of the combination 0 IFN-y and relaxin in decreasing 
coliagen expression by scleroderma fibroblasts in vitro. We have 
found that in four of seven scleroderma lines, relaxin was able to 
augment the collagen-depressing effect of INF-y. In three of the 
bnes, the addition of relaxin to cultures in combination with subop-
timal concentrations of IFN -y resulted in decreases in collagen ex-
pression equivalent to or better than that obtained by IFN-y alone at i t<:nf?ld higher concentration. This demonstrates that usi~g re-
aXIn In conjunction with IFN-y may allow for a reduction m t~e 
concentration ofIFN-y necessary to achieve a significant decrease m 
COliagen expression. In another of the lines, which was relatively 
Insensitive to either relaxin or IFN-y when used individually, the 
Combination of cytokines at the maximum in vitro doses 'effected an 
additive decrease in collagen secretion. 
Because relaxin is a naturally occurring hormone of pregnancy 
[12], it is likely to be well-tolerated if given exogenously. In addi-
tion, studies published in the late 1950s and early 1960s reported 
sOme efficacy of partially purified procine relaxin in the treatment 
of scleroderma patients [28,29]' particularly with regard to increas-
Ing skin elasticity and healing of skin ulcers. However, the ability of 
relaxin to be evaluated further was limited by uncertainties con-
cerning the source and purity of relaxin preparations [29]. The 
availability of highly purified, human recombinant relaxin will now 
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allow a full evaluation of its potential role, alone and in combination 
with IFN-y, as a modulator of excessive collagen synthesis in vitro 
and in vivo. 
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